New Products: Cancer Genetics' UroGenRA-Kidney Array | GenomeWeb

Cancer Genetics, a Rutherford, NJ-based provider of oncology-focused molecular testing services, recently introduced UroGenRA-Kidney, a microarray intended for kidney cancer diagnosis and subtyping.

According to the company, the test is being offered in compliance with the US Clinical Laboratory Improvement Amendment and the approval of the New York State Department of Health. CGI said that the test will be offered to clients as part of its Kidney Complete Program, a suite of tests for kidney cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?